Preclinical studies in TNBC demonstrated that tavo therapy expanded and activated CD8+ T cells via a CXCR3 gene signature, induced PD-1/PD-L1 expression, and led to tumor regression and long-term survival [266]. The gene discussed is CD8A; the disease is neoplasm.